Nuvalent

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why

Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why

CAMBRIDGE, Mass. , May 24, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors Strong financial position with expected operating runway into the second half of 2025 CAMBRIDGE, Mass. , May 11, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced plans to share preliminary data from the dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial for NVL-655, a novel ALK-selective inhibitor, in the second half of 2023, and reported first quarter 2023 financial results.

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass. , April 19, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting the intracranial activity NVL-655. NVL-655 is a brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) designed to maintain activity against ALK and ALK mutations that confer resistance to currently approved therapies, and to avoid neurological adverse events and dose-limiting toxicities associated with TRK inhibition.

Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

Significant progress made across pipeline of novel kinase inhibitors with parallel-lead programs in ongoing Phase 1 clinical trials and a third program advancing toward clinical development   Strengthened leadership team with key internal promotions Strong financial position with $472 million in cash, cash equivalents and marketable securities to support operating runway into the second half of 2025 CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline and business progress and fourth quarter and full year 2022 financial results.

Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

CAMBRIDGE, Mass. , March 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

Boeing

Caterpillar

Celsius Holdings

Clearfield

Vita Coco

Chevron

DocGo

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Noble Corp PLC

Northern Oil and Gas

Permian Basin Royalty Trust

Pinduoduo Inc - ADR

Tidewater

TG Therapeutics

Mammoth Energy Services

Visa

Vipshop Hlds

Viridian Therapeutics

Verizon

Wave Life Sciences

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

Surprisingly, Nuvalent, Inc. has attracted a lot of market interest over the past year, while known headwinds have put the entire biotech sector under strong upward pressure. As a result, Nuvalent stock appears overvalued compared to its portfolio of treatments in development.

Nuvalent Looks Overvalued After A Rapid Rally

Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case studies CAMBRIDGE, Mass. , Dec. 13, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1.

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Dow Inc

Futu Holdings

Honeywell

Brigham Minerals

NIKE

AiHuiShou International Co Ltd

SPDR S&P 500 ETF Trust

TAL Education Group

Zymeworks Inc

Zynex Inc

Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT hit +6.22% and CPRX +4.4%.

MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An Edge

Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going

G-III Apparel Group

Goldman Sachs

Intel

Lattice Semiconductor

Two new Breakout Stocks for Week 47 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +123.7% YTD. This week 2 of 4 picks gained 10%+ in less than a week with FUTU +23.6% and FREY 14.0% of the high frequency breakout movers. VIPS peaked at +9.64%.

MDA Breakout Stocks Week 47 - Short-Term Picks To Give You An Edge

Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?

Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC Enrollment progressing in ALKOVE-1 Phase 1/2 trial with parallel-lead candidate, NVL-655, for ALK-positive NSCLC NVL-330 demonstrates potency and selectivity for HER2 Exon 20 insertion mutations, and brain penetration in preclinical studies $264.5 million upsized public offering along with cash, cash equivalents, and marketable securities as of September 30, 2022 expected to extend operating runway into second half of 2025 CAMBRIDGE, Mass. , Nov. 10, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent business and pipeline progress and third quarter 2022 financial results.

Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results

Clean Energy Fuels

ConocoPhillips

Cheniere Energy

MAG Silver

MGP Ingredients

RingCentral

TravelCenters of America

Travelers

Encore Wire

Two new Breakout Stocks for Week 45 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +109.9% YTD. This week one stock gained 10% in less than a week with EPM +10.6% and GWH +7.6% while ENVX missed Q3 earnings for a terrible -41.7% decline.

MDA Breakout Stocks Week 45 - November 2022: Short-Term Picks To Give You An Edge

Recent IPO stock Nuvalent Therapeutics surged within striking distance of a record high Friday on promising test results in lung cancer. The post Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win appeared first on Investor's Business Daily.

Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win

Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment-related dizziness, or adverse events leading to treatment reductions or discontinuations as of the data cut-off date Encouraging preliminary signs of activity observed across all dose levels in heavily pre-treatedpatients with ROS1-positive NSCLC, including in subgroups of patients with G2032R resistance mutation or with brain metastases Company to host conference call today at 8:30 am EDT CAMBRIDGE, Mass. , Oct. 28, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors.

Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant NVL-655 preclinical data further support its best-in-class potential for patients with advanced ALK-positive NSCLC and other solid tumors Data Presented at the 34th EORTC-NCI-AACR (ENA) Symposium CAMBRIDGE, Mass. , Oct. 26, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for NVL-330, its recently nominated HER2-selective inhibitor, and NVL-655, its ALK-selective inhibitor currently under investigation in the ALKOVE-1 Phase 1/2 study for advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.

Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m.

Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium

CAMBRIDGE, Mass. , Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L.

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

News for Nuvalent Stock (NUVL)